Blonanseryna jest antagonistą receptorów dopaminergicznychD2 i D3. Wykazuje też powinowactwo do szeregu innych receptorów, w tym postsynaptycznych receptorów serotoninowych 5-HT2A.
↑M. Murasaki. Clinical evaluation of blonanserin for schizophrenia: a double-blind trial comparing blonanserin with haloperidol. „Japanese Journal of Clinical Pharmacology and Therapeutics”. 10, s. 2059–2079, 2007.
↑S. Miura. Clinical evaluation of blonanserin for schizophrenia: a randomized controlled study comparing blonanserin with risperidone. „Japanese Journal of Clinical Pharmacology and Therapeutics”. 11, s. 297–314, 2008.
↑J. Yang, W.M. Bahk, H.S. Cho, Y.W. Jeon i inni. Efficacy and tolerability of Blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial. „Clinical Neuropharmacology”. 33 (4), s. 169–175, 2010. DOI: 10.1097/WNF.0b013e3181dcda50. PMID: 20661022.
↑Y.G. Wen, D.W. Shang, H.Z. Xie, X.P. Wang i inni. Population pharmacokinetics of blonanserin in Chinese healthy volunteers and the effect of the food intake. „Human Psychopharmacology: Clinical and Experimental”. 28 (2), s. 134–141, 2013. DOI: 10.1002/hup.2290. PMID: 23417765.